Trial reportBMC urology2006
Intraprostatic injection of botulinum toxin type-A relieves bladder outlet obstruction in human and induces prostate apoptosis in dogs.
Trial report in BMC urology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 95 citations in OpenAlex.
- Botulinum neurotoxin type A for the treatment of benign prostatic hyperplasia: randomized study comparing two doses.TheScientificWorldJournal · 2012Trial
- Intraprostatic Botulinum Toxin Type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment.BMC urology · 2009Trial
- [Botulinum toxin in male lower urinary tract symptoms (LUTS): What can we expect?]Urologie (Heidelberg, Germany) · 2024Review
- Therapeutic Applications of Botulinum Neurotoxins in Veterinary Medicine.Veterinary sciences · 2023Review
- Review
- Use of botulinum toxin for voiding dysfunction.Translational andrology and urology · 2017Review
- Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.Pharmacological reviews · 2017Review
- Botulinum Toxin A and Lower Urinary Tract Dysfunction: Pathophysiology and Mechanisms of Action.Toxins · 2016Review
- Apoptotic action of botulinum toxin on masseter muscle in rats: early and late changes in the expression of molecular markers.SpringerPlus · 2016Article
- New intraprostatic injectables and prostatic urethral lift for male LUTS.Nature reviews. Urology · 2015Review
- Lower urinary tract symptoms in men.BMJ (Clinical research ed.) · 2014Review
- Botulinum toxin A inhibits salivary secretion of rabbit submandibular gland.International journal of oral science · 2013Article
- [Intraprostatic injection therapy in patients with benign prostatic syndrome].Der Urologe. Ausg. A · 2013Article
- [New treatment strategies for male lower urinary tract symptoms].Der Urologe. Ausg. A · 2012Article
- Expression of apoptosis-regulating genes in the rat prostate following botulinum toxin type A injection.BMC urology · 2012Article
- Emerging treatment options for benign prostatic obstruction.Current urology reports · 2011Review
- A review of botulinum toxin use for chronic pelvic pain syndrome.Current urology reports · 2010Review
- Ten years single surgeon experience with botulinum toxin in the urinary tract; clinical observations and research discovery.International urology and nephrology · 2010Review
- [Botulinum toxin in the treatment of benign prostatic hyperplasia : an overview].Der Urologe. Ausg. A · 2008Review
- Injection therapy for prostatic disease: A renaissance concept.Indian journal of urology : IJU : journal of the Urological Society of India · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWith the increasing interest with botulinum toxin--A (BTX-A) application in the lower urinary tract, we investigated the BTX-A effects on the canine prostate and also in men with bladder outlet obstruction (BOO) due to benign prostatic hyperplasia (BPH).
methodsTransperineal injection into the prostate using transrectal ultrasound (TRUS) was performed throughout the study. Saline with or without 100 U of BTX-A was injected into mongrel dogs prostate. One or 3 months later, the prostate was harvested for morphologic and apoptotic study. In addition, eight BPH patients refractory to alpha-blockers were treated with ultrasound guided intraprostatic injection of 200 U of BTX-A.
resultsIn the BTX-A treated dogs, atrophy and diffuse apoptosis was observed with H&E stain and TUNEL stain at 1 and 3 months. Clinically, the mean prostate volume, symptom score, and quality of life index were significantly reduced by 18.8%, 73.1%, and 61.5% respectively. Maximal flow rate significantly increased by 72.0%.
conclusionIntraprostatic BTX-A injection induces prostate apotosis in dogs and relieves BOO in humans. It is therefore a promising alternative treatment for refractory BOO due to BPH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.